ERBB2 and breast cancer: Within the context of breast cancer, we commonly discuss the oncogenic role of amplification of HER2 and its use as an indicator of more aggressive tumor phenotypes that benefits from targeted therapies (i.e., trastuzumab) 34, 35, 36.